“I would not interpret that as implying a decline in GARDASIL in China over the coming years.”

In context

“t contracts as you work through warehouse patients. Is that how we should think about the longer-term uptake of GARDASIL in that particular market that it might not be linear? Robert Davis: Yes. Just -- so if you look at the GSA contract, it's important to understand that the levels put in that contract are minimums. And in fact, we have shown and our history has been that actually we have supplied well over the minimum. So I wouldn't interpret that as the literal forecast of the business in China because there's opportunities with the expanded age cohorts as we continue to drive penetration in what is still a large unmet population, there is opportunities to do better than what's in that contract. And if history isn't indicative of the future, we would expect to see that move forward. So I would not interpret that as implying a decline in GARDASIL in China over the coming years. Caroline Litchfield: The only thing I would add is from a research perspective, we remain focused on studies in China to support gender-neutral vaccination, which could be a great opportunity to protect more lives and provide growth into the future. Peter Dannenbaum: Great. Thank you, Tim. Next question, please. Operator: Evan Seigerman with BMO Capital Markets. Unidentified Analyst: This is [Ng Ma] hopping on for Evan. We wanted to ask with the sotatercept Phase 3 data, the Prometheus deal and novel assets like the oral PCSK9, does the team now think that this will be enough to grow through the KEYTRUDA LOE? Robert Davis: Yes. I'll take the question, Evan. Obviously, I would start by saying we feel very good about the progress we've made in a very short period of time. So if you look at”